On the hypolipemic properties of bendaline.
Bendaline, like tiadenol, clofibrate and clofibric acid generally inhibits: a) some hyperlipemias and lipoidoses induced by either an increased exogenous supply of lipids or the stimulation of cholesterol synthesis or mobilization of lipids; b) platelet aggregation in vitro.
D000818:Animals; D001646:Bile / Q000378:metabolism; D002791:Cholesterol, Dietary / Q000009:adverse effects; D005260:Female; D005632:Fructose / Q000633:toxicity; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007191:Indazoles / Q000494:pharmacology / Q000627:therapeutic use*; D008064:Lipidoses / Q000188:drug therapy*; D008108:Liver Diseases, Alcoholic / Q000188:drug therapy*; D008297:Male; D008315:Malondialdehyde / Q000096:biosynthesis; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects; D011720:Pyrazoles / Q000627:therapeutic use*; D011817:Rabbits; D051381:Rats
D002791:Cholesterol, Dietary; D000960:Hypolipidemic Agents; D007191:Indazoles; D011720:Pyrazoles; D005632:Fructose; D008315:Malondialdehyde; C036067:bendazac lysine